- Home
- Publications
- Publication Search
- Publication Details
Title
Blood Neurofilament Light in Progressive Multiple Sclerosis
Authors
Keywords
-
Journal
NEUROLOGY
Volume 98, Issue 21, Pages e2120-e2131
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-04-05
DOI
10.1212/wnl.0000000000200258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
- (2021) Claire Bridel et al. NEUROLOGY
- Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud
- (2021) Carolyn Goldschmidt et al. NEUROLOGY
- Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis
- (2020) Rosa Cortese et al. Multiple Sclerosis Journal
- Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis
- (2020) Ali Manouchehrinia et al. NEUROLOGY
- Serum neurofilament light as a biomarker in progressive multiple sclerosis
- (2020) Raju Kapoor et al. NEUROLOGY
- Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study
- (2020) Stefan Bittner et al. EBioMedicine
- Long-term prognostic value of longitudinal measurements of blood neurofilament levels
- (2020) Dieter A. Häring et al. Neurology-Neuroimmunology & Neuroinflammation
- Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
- (2019) Jens Kuhle et al. NEUROLOGY
- Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
- (2019) Maria Pia Sormani et al. Annals of Clinical and Translational Neurology
- Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
- (2019) Ester Cantó et al. JAMA Neurology
- Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study
- (2019) Dejan Jakimovski et al. Multiple Sclerosis Journal
- Correlation between EDSS scores and cervical spinal cord atrophy at 3T MRI in multiple sclerosis: A systematic review and meta-analysis
- (2019) Xiaodong Song et al. Multiple Sclerosis and Related Disorders
- Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
- (2018) Christian Barro et al. BRAIN
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- Preferential spinal cord volume loss in primary progressive multiple sclerosis
- (2018) Charidimos Tsagkas et al. Multiple Sclerosis Journal
- Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
- (2018) Nelly Siller et al. Multiple Sclerosis Journal
- Preferential spinal cord volume loss in primary progressive multiple sclerosis
- (2018) Charidimos Tsagkas et al. Multiple Sclerosis Journal
- Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
- (2018) Nelly Siller et al. Multiple Sclerosis Journal
- Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
- (2018) Tanuja Chitnis et al. Annals of Clinical and Translational Neurology
- Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
- (2017) Daniel Ontaneda et al. LANCET
- Clinical outcome measures for progressive MS trials
- (2017) Daniel Ontaneda et al. Multiple Sclerosis Journal
- Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
- (2017) Fredrik Piehl et al. Multiple Sclerosis Journal
- Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
- (2017) Lenka Novakova et al. NEUROLOGY
- Clinical outcome measures for progressive MS trials
- (2017) Daniel Ontaneda et al. Multiple Sclerosis Journal
- Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
- (2017) Fredrik Piehl et al. Multiple Sclerosis Journal
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
- (2015) Anthony Feinstein et al. LANCET NEUROLOGY
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Cognitive impairment differs between primary progressive and relapsing-remitting MS
- (2013) A. Ruet et al. NEUROLOGY
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now